GJB2-related hearing loss is the most prevalent form of genetic hearing loss, and a successful gene therapy could eventually offer a biological treatment alternative to hearing aids and cochlear implants for this population.

Hearing Review·Regulatory·Regulatory & legal·7w ago

Sensorion Receives French Regulatory Approval to Initiate HearConnex Gene Therapy Trial for GJB2-Related Hearing Loss

If successful, GJB2-targeted gene therapy could offer a biological hearing restoration option for the most common form of inherited congenital deafness, fundamentally shifting the treatment landscape beyond hearing aids and cochlear implants.

✦ Search

✦ Filter

2 dispatches

✦ Top desks

All →

PubMed2833
ASHA Voices313
Hearing Health Matters271
Hearing Practitioner Australia236
Hearing Review233
Doctor Cliff, AuD228
Hearing Tracker214
The Hearing Journal Podcast200
Aurahear195
RNID168
Hear Us Out130
Audiology Worldnews119
The Hearing Matters Podcast113
AudiologyOnline105
Tinnitus Relief w/ Dr. Ben Thompson105
Future Ear Radio100

The Hearing Wirebroadsheet

An editorialised feed of audiology, hearing-health, and industry signals — gathered from the desks audiologists already trust.

✦ The Desks

Live dispatches
Story clusters
All sources
Research watch
Industry watch

✦ The Masthead

About this paper
Editorial policy
HearingTracker
Contact the editor

✦ Search

✦ Filter

2 dispatches